Literature DB >> 14678049

Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis.

Enver Akalin, Jonathan S Bromberg, Vinita Sehgal, Scott Ames, Barbara Murphy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14678049     DOI： 10.1046/j.1600-6143.2003.00308.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN： 1600-6135            Impact factor:   8.086


× No keyword cloud information.
  7 in total

Review 1.  Viral surveillance and subclinical viral infection in pediatric kidney transplantation.

Authors:  Jodi M Smith; Vikas R Dharnidharka
Journal:  Pediatr Nephrol       Date:  2014-08-16       Impact factor: 3.714

2.  Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients.

Authors:  Hannah Imlay; Allison O Dumitriu Carcoana; Cynthia E Fisher; Beatrice Wong; Robert M Rakita; Daniel P Fishbein; Ajit P Limaye
Journal:  Transpl Infect Dis       Date:  2020-02-20       Impact factor: 2.228

3.  Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.

Authors:  A A Boudreault; H Xie; R M Rakita; J D Scott; C L Davis; M Boeckh; A P Limaye
Journal:  Transpl Infect Dis       Date:  2011-03-17       Impact factor: 2.228

4.  Efficacy and safety of a lower-dose valganciclovir (valcyte) regimen for cytomegalovirus prophylaxis in kidney and pancreas transplant recipients.

Authors:  Vrinda Bhat; Megan McIntyre; Tracey Meyers
Journal:  P T       Date:  2010-12

5.  Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection.

Authors:  Fu L Luan; Linda J Stuckey; Jeong M Park; Daniel Kaul; Diane Cibrik; Akinlolu Ojo
Journal:  J Am Soc Nephrol       Date:  2009-09-17       Impact factor: 10.121

6.  Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients.

Authors:  C E Chamberlain; S R Penzak; R M Alfaro; R Wesley; C E Daniels; D Hale; A D Kirk; R B Mannon
Journal:  Am J Transplant       Date:  2008-04-29       Impact factor: 8.086

Review 7.  Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis.

Authors:  Siavash Vaziri; Zohre Pezhman; Babak Sayyad; Feizolla Mansouri; Alireza Janbakhsh; Mandana Afsharian; Farid Najafi
Journal:  J Res Med Sci       Date:  2014-12       Impact factor: 1.852
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.